English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, December 14, 2023
Eisai and Mizuho Sign Sustainability-Linked Loan Agreement
"LEQEMBI Intravenous Infusion" (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20
Thursday, December 10, 2020
アデュカヌマブ、日本において新薬承認を申請
Monday, July 20, 2020
エーザイ、人事異動(2020年7月20日付)を発表
Wednesday, July 31, 2019
エーザイ、2020年3月期配当予想の修正(増配)に関するお知らせ
Monday, December 11, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
Thursday, November 30, 2023
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Wednesday, November 22, 2023
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
Monday, November 20, 2023
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
Wednesday, October 25, 2023
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575